The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Open accessAbstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“proteome-wide mass-spectrometry demonstrated selective degradation of endogenous IKZF1/3, and ZFP91 in multiple cell lines (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide, lenalidomide and pomalidomide mediate CRL4CRBN-dependent degradation of a larger number of proteins than previously appreciated through a C2H2 ZF degron (3, 4, 16).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both thalidomide and lenalidomide lack specificity for iKZF2 (Krönke et al. 2014;lu et al. 2014), as it encodes a histidine in a critical thalidomidebinding position.”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mechanistic studies later confirmed that the efficacy of lenalidomide in 5q-MDS was actually due to the recruitment of an unexpected neo-substrate: the kinase cK1α (CSNK1A1) which resides within the long arm of chromosome 5 (5q32) (Krönke et al. 2014) (Figure 5B, i).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“lenalidomide was shown to promote the interaction between cRBN and two members of the ikaros transcription factor family: iKZF1 and iKZF3 (gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
The cited source says what the claim attributes to it.
In the citing paper
“As such, lenalidomide can promote the interaction between cRl4 cRBN and both iKZF1 and iKZF3 resulting in their selective degradation which disrupts their role at gene promoters (Krönke et al. 2014;lu et al. 2014).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Krönke et al. 2014
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [10]
In the citing paper
“As described before, in the presence of IMiDs, CRBN E3 ligase induces the proteasomal degradation of a set neo-substrates, such as IKZF1/3[13,39], CK1α[40] and GSPT1[15].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [13]
In the citing paper
“This is further supported by the observations that PZ could selectively induce Bcl-xl but not Bcl-2 poly-ubiquitination and had no significant effect on the expression of the CRBN native substrate, glutamine synthetase (GS)36, and its neosubstrates recruited by thalidomide and its analogues including CK1α37, IKZF1, and IKZF3 (ref. 38) (Supplementary Fig. 1 f, g).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [38]
In the citing paper
“In brief, IMiDs bind the E3 ligase cereblon (CRBN), thus complementing a surface patch that subsequently recruits a variety of C2H2 zinc finger transcription factors for ubiquitination and degradation.48−51”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [50]
In the citing paper
“In brief, IMiDs were first shown to trigger CRBN-dependent proteasomal degradation of the C2H2-type zing-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).[46][47][48]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“The presence of a glutamine residue in their second zing-finger domain enables IMiD-induced degradation, 47 while the histidine residues in Helios (IKZF2) do not.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [47]
In the citing paper
“thalidomide interacts with CRBN to form a novel surface, resulting in interactions with neosubstrates such as Ikaros (IKZF1) and Aiolos (IKZF3) and their ubiquitination and subsequent proteasomal degradation.20,21”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [20]
In the citing paper
“lenalidomide and pomalidomide induce CRBN-dependent ubiquitination and degradation of Ikaros and Aiolos, transcription factors required for the development of lymphoids and survival of multiple myeloma8–10.”
From Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide (2020) · cites this paper as [8]
In the citing paper
“Molecular glues, based on the serendipitous discovery that thalidomide and its analogues act as degrader molecules, constitute another important therapeutic class1–8.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“These drugs co-opt CRBN to target IKAROS family zinc finger 1 (IKZF1) and IKZF3 for degradation3,4,24, and are now considered as pioneering examples of molecular glues.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“CRBN appears to be emerging as a preferred E3 ligase for the first wave of TPD therapeutics in clinical trials.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“Examples here include the approved IMiD class, which relies on CRBN to degrade IKZF1/IKZF3 (refs4,5) via a molecular glue mechanism”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [4]
In the citing paper
“thalidomide and its analogues do not inhibit the enzymatic activity of CRL4CRBN, but instead confer neomorphic activity on CRBN to mediate the selective ubiquitination and resultant proteasomal degradation of the transcription factors Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 (Aiolos) in MM cells and T cells11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“In 2013, thalidomide analogues were discovered to exert their therapeutic effects by acting as a molecular glue to recruit disease-relevant neosubstrate proteins to an E3 ubiquitin ligase, resulting in neosubstrate ubiquitination and, ultimately, proteasomal degradation11–13.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“given that proteasome inhibitors antagonize lenalidomide-induced protein degradation11,12,55.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Most known neosubstrate proteins have been identified through proteomic analyses of different cell lineages11,15,165,166.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [11]
In the citing paper
“Ebert's gourp and Kaelin Jr's group independently demonstrated that when lenalidomide binds to CRBN, a new function of CRBN is induced, namely, to ubiquitinate and degrade Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors that are known to be responsible for the maturation of B cells [25,26].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [25]
In the citing paper
“CRBN was shown to bind the drug thalidomide in its substrate binding pocket, thereby creating a new surface to recruit other proteins for ubiquitination and degradation, such as the transcription factors Ikaros and Aiolos (IKZF1 and 3, respectively) or the kinase CK1α [70–72].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [72]
In the citing paper
“The clinical efficacy of IMiDs is driven at least in part by their capacity to induce CRBN-mediated degradation of neo-substrates: cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
In the citing paper
“cancer cells become resistant to the multiple myeloma IMiD drug lenalidomide upon mutation of a single amino acid in IKFZ3 that rescues this transcription factor from proteolytic degradation 7 ;”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan‐Smith, E., Dalton, J., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,777
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)
Ong, S., & Mann, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.427 · Cited by 917
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,006
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
Self-citationSelectivity through Targeted Protein Degradation (TPD)
Gopalsamy, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00397 · Cited by 45
Managing treatment-related peripheral neuropathy in patients with multiple myeloma
Petrucci, M. T., Cesini, L., & Grammatico, S. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s91251 · Cited by 46
Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity
Sebastian, S., Zhu, Y. X., Braggio, E., Shi, C.-X., Panchabhai, S. C., Wier, S. A. V., Ahmann, G. J., Chesi, M., Bergsagel, P. L., Stewart, A. K., et al. (2016) · Blood · doi:10.1182/blood-2016-09-738872 · Cited by 45
Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Reme, T. X., Robert, N., Requirand, G., Boireau, S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0025-x · Cited by 48
Perry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
Factors Regulating microRNA Expression and Function in Multiple Myeloma
Misiewicz-Krzemińska, I., Krzemiński, P., Corchete, L. A., Quwaider, D., Rojas, E. A., Herrero, A. B., & Gutierrez, N. C. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010009 · Cited by 48
Mechanisms of lenalidomide sensitivity and resistance
Martínez-Høyer, S., & Karsan, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.196 · Cited by 48
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 45
USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Nguyen, T. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111391118 · Cited by 49
Emerging strategies for prospective discovery of molecular glue degraders
Wang, B., Cao, S., & Zheng, N. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102811 · Cited by 47
Rees, M. J., & Kumar, S. K. (2024) · American Journal of Hematology · doi:10.1002/ajh.27327 · Cited by 48
Routes to molecular glue degrader discovery
Liu, Y., Bai, J., Li, D., & Cang, Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.006 · Cited by 51
Xu, Q., Hou, Y.-X., Langlais, P. R., Erickson, P. W., Zhu, J. J., Shi, C.-X., Luo, M., Zhu, Y., Xu, Y., Mandarino, L. J., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2331-0 · Cited by 45
Hemoglobin genetics: recent contributions of GWAS and gene editing
Smith, E. C., & Orkin, S. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw170 · Cited by 45
Carbonneau, S., Sharma, S. P., Peng, L., Rajan, V., Hainzl, D., Hénault, M., Yang, C., Hale, J. A., Shulok, J. R., Tallarico, J. A., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.012 · Cited by 47
Shen, C., Nayak, A., Neitzel, L. R., Adams, A. A., Silver-Isenstadt, M., Sawyer, L. M., Benchabane, H., Wang, H., Bunnag, N., Li, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25634-z · Cited by 43
Targeting oncoproteins with a positive selection assay for protein degraders
Koduri, V., Duplaquet, L., Lampson, B. L., Wang, A. C., Sabet, A. H., Ishoey, M., Paulk, J., Teng, M., Harris, I. S., Endress, J. E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6263 · Cited by 44
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 45
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives
Nowak, R. P., Che, J., Ferrao, S., Kong, N. R., Liu, H., Zerfas, B. L., & Jones, L. H. (2023) · RSC Medicinal Chemistry · doi:10.1039/d2md00347c · Cited by 45
Deregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 45
Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues
Hassan, M. M., Li, Y.-D., Ma, M. W., Teng, M., Byun, W. S., Puvar, K., Lumpkin, R. J., Sandoval, B., Rutter, J. C., Jin, C. Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116904 · Cited by 45
Self-citationNanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology
Baker, A., Ho, A. P. T., Itzhaki, L. S., & Fruk, L. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202503958 · Cited by 44
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Lill, J. R., & Wertz, I. E. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.01.005 · Cited by 47
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Zitti, B., Molfetta, R., Fionda, C., Quatrini, L., Stabile, H., Lecce, M., de Turris, V., Ricciardi, M. R., Petrucci, M. T., Cippitelli, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10403-0 · Cited by 44
Patil, A., Manzano, M., & Gottwein, E. (2018) · Blood · doi:10.1182/blood-2018-01-828418 · Cited by 45
Chen, H., Chen, F., Pei, S., & Gou, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.035 · Cited by 44
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Hao, B., Li, X., Jia, X., Wang, Y., Zhai, L., Li, D., Liu, J., Zhang, D., Chen, Y.-L., Xu, Y., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0367-9 · Cited by 45
Self-citationLeblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 47
Matyskiela, M. E., Zhu, J., Baughman, J. M., Clayton, T., Slade, M., Wong, H. K., Danga, K., Zheng, X., Labow, M., LeBrun, L. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00674 · Cited by 45
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., Vacca, A., & Montagnani, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092513 · Cited by 46
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 48
The application of PROTAC in HDAC
Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 45
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Kagiou, C., Cisneros, J. A., Farnung, J., Liwocha, J., Offensperger, F., Dong, K. D., Yang, K., Tin, G., Horstmann, C. S., Hinterndorfer, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49739-3 · Cited by 46
Kumar, S., Venkatachalapathy, M., Sistla, R. K., & Poongavanam, V. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104205 · Cited by 43
The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage
Wani, T. H., Chakrabarty, A., Shibata, N., Yamazaki, H., Guengerich, F. P., & Chowdhury, G. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00127 · Cited by 43
PROTACs: New method to degrade transcription regulating proteins
Hu, B.-C., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 43
Self-citationDevelopment of CDK4/6 Inhibitors: A Five Years Update
Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 48
Development of Photolenalidomide for Cellular Target Identification
Lin, Z., Amako, Y., Kabir, F., Flaxman, H. A., Budnik, B., & Woo, C. M. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c11920 · Cited by 44
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Swan, D., Murphy, P. T., Glavey, S. V., & Quinn, J. (2023) · Cancers · doi:10.3390/cancers15061819 · Cited by 42
O’Connor, H. F., & Huibregtse, J. M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2529-6 · Cited by 42
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
Quality control of protein complex composition
Padovani, C., Jevtić, P., & Rapé, M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.029 · Cited by 46
Chen, K., Cai, J., Wang, S., Li, Y., Yang, C., Fu, T., Zhao, Z., Zhang, X., & Tan, W. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202208451 · Cited by 42
PROTACS: A technology with a gold rush-like atmosphere
Wang, Y., Lan, L., Wang, M., Zhang, J., Gao, Y., Shi, L., & Sun, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115037 · Cited by 44
Welsh, S. J., Barwick, B. G., Meermeier, E. W., Riggs, D. L., Shi, C.-X., Zhu, Y. X., Sharik, M. E., Du, M. T., Rocha, L. D. A., Garbitt, V. M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0062 · Cited by 44
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
Bolomsky, A., Ceribelli, M., Scheich, S., Rinaldi, K., Huang, D. W., Chakraborty, P., Pham, L., Wright, G. W., Hsiao, T., Morris, V. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.026 · Cited by 46
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 61
Kang, J., Park, S., Jeong, S. P., Han, M., Lee, C., Lee, K. M., Kim, N., Song, M., Choi, M., Ye, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502166113 · Cited by 42
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 43
Cereblon Maintains Synaptic and Cognitive Function by Regulating BK Channel
Choi, T.-Y., Lee, S., Kim, Y.-J., Bae, J. R., Lee, K. M., Jo, Y., Kim, S., Lee, A.-R., Choi, S., Choi, L., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2081-17.2018 · Cited by 42
Momtaz, S., Memariani, Z., El‐Senduny, F. F., Sanadgol, N., Golab, F., Katebi, M., Abdolghaffari, A. H., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00361 · Cited by 46
B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy
Jiang, L., & Li, N. (2020) · Angiogenesis · doi:10.1007/s10456-020-09729-7 · Cited by 42
Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.013 · Cited by 41
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Gismondi, A., Santoni, A., & Fionda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031103 · Cited by 42
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
Hanzl, A., Barone, E., Bauer, S., Yue, H., Nowak, R. P., Hahn, E., Pankevich, E. V., Koren, A., Kubicek, S., Fischer, E. S., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10784 · Cited by 40
Simoes, R. D. M., Shirasaki, R., Downey-Kopyscinski, S. L., Matthews, G. M., Barwick, B. G., Gupta, V. A., Dupéré-Richer, D., Yamano, S., Hu, Y., Sheffer, M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00550-x · Cited by 40
Self-citationEmerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 42
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 42
Eladl, O. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117297 · Cited by 44
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
Lesokhin, A. M., Bal, S., & Badros, A. Z. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0148 · Cited by 40
New generation drugs for treatment of multiple myeloma
Alanazi, F. G., Kwa, F. A. A., Burchall, G., & Jackson, D. E. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.008 · Cited by 41
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 43
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor‐Ruiz, C., & Winter, G. E. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 44
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 43
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
Wu, W., Nelson, G. M., Koch, R., Donovan, K. A., Nowak, R. P., Heavican, T. B., Nirmal, A. J., Liu, H., Yang, L., Duffy, J., et al. (2021) · Blood · doi:10.1182/blood.2021014701 · Cited by 40
Jain, D., Hodonsky, C. J., Schick, U. M., Morrison, J., Minnerath, S., Brown, L., Schurmann, C., Liu, Y., Auer, P. L., Laurie, C. A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx024 · Cited by 40
Nelde, A., Kowalewski, D. J., Backert, L., Schuster, H., Werner, J.-O., Klein, R., Kohlbacher, O., Kanz, L., Salih, H. R., Rammensee, H., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1316438 · Cited by 40
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Ioannou, N., Jain, K., & Ramsay, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168572 · Cited by 41
The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound
Shortt, J., Hsu, A., Martin, B. P., Doggett, K., Matthews, G. M., Doyle, M., Ellul, J., Jockel, T. E., Andrews, D. M., Hogg, S. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.008 · Cited by 39
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
Chen, S., Chen, Z., Lu, L., Zhao, Y., Zhou, R., Xie, Q., Shu, Y., Lin, J., Yu, X., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115403 · Cited by 39
Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1
Meyers, M., Cismoski, S., Panidapu, A., Chie-Leon, B., & Nomura, D. K. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.3c00487 · Cited by 46
New strategies to enhance the efficiency and precision of drug discovery
An, Q., Huang, L., Wang, C., Wang, D., & Tu, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1550158 · Cited by 45
SPLINTS: small-molecule protein ligand interface stabilizers
Fischer, E. S., Park, E., Eck, M. J., & Thomä, N. H. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.004 · Cited by 39
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 41
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Is PROTAC technology really a game changer for central nervous system drug discovery?
Farrell, K., & Jarome, T. J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1915979 · Cited by 39
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 41
Li, F., Aljahdali, I. A. M., & Ling, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116206 · Cited by 38
Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis
Ikura, H., Endo, J., Kitakata, H., Moriyama, H., Sano, M., & Fukuda, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116336 · Cited by 26
Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Lin, J., Liu, H., Wu, Y., Jin, J., Zhou, Y., Zhang, H., Nagle, D. G., Chen, H., Zhang, W., & Luan, X. (2023) · Small · doi:10.1002/smll.202207778 · Cited by 38
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Forster, S., Radpour, R., & Ochsenbein, A. F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1243997 · Cited by 44
Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
Hao, B., Chen, K., Zhai, L., Liu, M., Liu, B., & Tan, M. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae019 · Cited by 41
Chemical biology approaches to target validation in cancer
Blagg, J., & Workman, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.007 · Cited by 38
Pizzi, M., Boi, M., Bertoni, F., & Inghirami, G. (2016) · Leukemia · doi:10.1038/leu.2016.161 · Cited by 40
Lenalidomide in the treatment of chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313230 · Cited by 40
Proteomics-Based Identification of DUB Substrates Using Selective Inhibitors
Bushman, J. W., Donovan, K. A., Schauer, N. J., Liu, X., Hu, W., Varca, A. C., Buhrlage, S. J., & Fischer, E. S. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.09.005 · Cited by 38
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 40
Zhao, G., Wei, R., Feng, L., Wu, Y., He, F., Xiao, M., & Zhi, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02959-8 · Cited by 38
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 38
Monteleone, S., Fedorov, D. G., Townsend‐Nicholson, A., Southey, M. W. Y., Bodkin, M. J., & Heifetz, A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00457 · Cited by 40
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 40
Self-citationApplications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 41
From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
Licht, J. D., Shortt, J., & Johnstone, R. W. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.019 · Cited by 37
Gendron, J. M., Webb, K. J., Yang, B., Rising, L., Zuzow, N., & Bennett, E. J. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058420 · Cited by 34
Nishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 39
Metadata
- Authors
- Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., Ciarlo, C., Hartman, E., Munshi, N., Schenone, M., Schreiber, S. L., Carr, S. A., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Ebert, Benjamin L.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 301-305
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4077049
- OpenAlex
- W2015345028
- Semantic Scholar
- bf4fc60d821257f664ef758f219b75586ad0adaa
- Cited by
- 1,879
- References
- 31
- Citations by year
- 2026: 159 · 2025: 188 · 2024: 185 · 2023: 169 · 2022: 176 · 2021: 196 · 2020: 186 · 2019: 138 · 2018: 125 · 2017: 100 · 2016: 102 · 2015: 88 · 2014: 59
- FWCI
- 37.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5p01ca078378-15)
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Human Genome Research Institute (RL1HG004671)
- National Cancer Institute (P01-CA078378, P50CA100707, P01CA108631, P01CA155258)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, multiple myeloma, IKZF1, IKZF3, selective protein degradation, E3 ubiquitin ligase, ubiquitination, mechanism of action, IL-2 production, T cells, transcription factors
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Interleukin-2, Multiple Myeloma, T-Lymphocytes, Thalidomide, Cell Line, Tumor, Ikaros Transcription Factor, Ubiquitination, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
